Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Heijde, D. van der; Durez, P.; Schett, G.; Naredo, E.; Ostergaard, M.; Meszaros, G.; ... ; Fleischmann, R. (2018)

Article / Letter to editor

• Baricitinib
• Joint damage
• Methotrexate
• RA-BEGIN study
• Rheumatoid arthritis
• Structural progression

• All authors: Heijde, D. van der; Durez, P.; Schett, G.; Naredo, E.; Ostergaard, M.; Meszaros, G.; Leonardis, F. de; Torre, I. de la; Lopez-Romero, P.; Schlichting, D.; Nantz, E.; Fleischmann, R.
• Date: 2018-09-30
• Journal: Clinical Rheumatology
• Volume: 37
• Issue: 9
• Pages: 2381 - 2390
• DOI: doi:10.1007/s10067-018-4221-0